CN109481442A — 一种紫杉醇和邻苯基酞嗪酮类btk抑制剂联合用药物组合物及其应用
Assigned to Nanjing Advanced Biomaterials And Process Equipment Research Institute Co Ltd · Expires 2019-03-19 · 7y expired
What this patent protects
本发明提供了一种紫杉醇和邻苯基酞嗪酮类BTK抑制剂联合用药物组合物,包含活性成分和药学上可接受的辅料,所述的活性成分由紫杉醇和式(I)所示的BTK抑制剂组成,所述活性成分中紫杉醇和式(I)所示的BTK抑制剂的摩尔比为(0.14‑0.20):1。该药物组合物可用于制备预防和/或治疗与布鲁顿酪氨酸激酶相关的疾病药物,治疗效果好。
USPTO Abstract
本发明提供了一种紫杉醇和邻苯基酞嗪酮类BTK抑制剂联合用药物组合物,包含活性成分和药学上可接受的辅料,所述的活性成分由紫杉醇和式(I)所示的BTK抑制剂组成,所述活性成分中紫杉醇和式(I)所示的BTK抑制剂的摩尔比为(0.14‑0.20):1。该药物组合物可用于制备预防和/或治疗与布鲁顿酪氨酸激酶相关的疾病药物,治疗效果好。
Drugs covered by this patent
- Imbruvica (ibrutinib) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.